

Sudeep Pharma (SUDEEPPH IN)

**Q4FY26 Result
Update**

May 22, 2026

Estimate Change | Target | Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	REDUCE		REDUCE	
Target Price	627		638	
Sales (INR mn)	7,276	8,191	7,276	8,217
% Chng.	-0.0	-0.3		
EBITDA (INR mn)	2,546	2,867	2,509	2,833
% Chng.	1.5	1.2		
EPS (INR)	17.3	19.0	18.1	19.9
% Chng.	-4.6	-4.7		

Key Data	SUDP.BO SUDEEPPH IN
BSE Code	544619
NSE Code	SUDEEPPHRM
52-W High / Low	INR 795 / INR 524
Face Value	1
Sensex / Nifty	75,415 / 23,719
Market Cap	INR 76 bn / \$ 795 mn
Shares Outstanding	112.95 mn
3M Avg. Daily Value	INR 75.47 mn

Shareholding Pattern (%)

Promoters	76.15
FIs	1.55
Mutual Funds	6.19
Domestic Institutions	11.92
Public & Others	4.18
Promoter's Pledge (INR bn)	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	(0.2)	1.3	-	-
Relative	3.9	11.2	-	-

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	5,020	6,423	7,276	8,191
EBITDA (INR mn)	1,900	2,219	2,546	2,867
Margin (%)	37.8	34.6	35.0	35.0
PAT (INR mn)	1,387	1,743	1,954	2,146
EV (INR mn)	66,452	77,417	76,671	76,492
Total Debt (INR mn)	1,353	1,483	1,943	2,143
C&C Eq. (INR mn)	368	267	1,326	1,706
EPS (INR)	14.3	15.4	17.3	19.0
Gr. (%)	(84.9)	8.1	12.1	9.8
DPS (INR)	-	-	-	-
Yield (%)	-	-	-	-
RoE (%)	32.7	25.3	19.9	18.1
RoCE (%)	33.9	25.0	20.5	18.6
EV/Sales (x)	13.2	12.1	10.5	9.3
EV/EBITDA (x)	35.0	34.9	30.1	26.7
PE (x)	47.2	43.6	38.9	35.4
P/BV (x)	13.3	8.6	7.1	5.9

Phase-1 of pCAM to commission by April'27

Quick Pointers

- Management expect PFN EBITDA to grow by ~15% in FY27 and FY28
- EBITDAM guidance of 37% in FY27

Sudeep Pharma reported consolidated revenue of Rs1.8bn in Q4FY26, registering growth of 16% YoY and 6% QoQ, while FY26 revenue increased 28% YoY to Rs6.4bn. The Specialty Ingredients (SI) segment reported revenue growth of 105% YoY and 26% QoQ, driven by higher demand across infant nutrition, medical nutrition and dietary supplements. The SI business contributed around 44% to FY26 revenue, EBIT margins remained largely stable. The Pharmaceutical, Food & Nutrition (PFN) segment declined 20% YoY and 9% QoQ; The management expects EBITDA growth of ~15% in the PFN business over FY27 and FY28, supported by higher capacity utilization. The company's pCAM project remains on track for Phase-1 commissioning by April'27, supported by rising global demand and China+1 sourcing opportunities.

Management has guided FY27 EBITDA margins of around 37%, while inventory levels to remain high to support customer demand and ensure raw material availability. The commissioning of the PFN expansion has been delayed due to customer validation timelines, which are expected to take around 6–12 months. The stock is currently trading at 35x FY28E EPS. We value the company at 33x FY28E EPS and maintain our 'Reduce' rating with a target price of Rs627.

Consolidated revenue increased 16%YoY/6%QoQ: Consolidated revenue stood at Rs1.8bn (16% YoY/ 6% QoQ). FY26 Revenue stood at Rs6.4bn increased by 28% YoY driven by speciality ingredients segment revenue grew by 105% YoY and 26% QoQ. Gross margin was at 65.3% (vs 62.1% in Q4FY25 and 65% in Q3FY26). Absolute Gross profit was at 1.2bn, increased 6% QoQ and 21%YoY

EBITDA increased 6%YoY/4%QoQ: EBITDA came in at Rs626mn (6% YoY/ 4% QoQ), and EBITDA margin came at 34.3% (vs 37.3% in Q4FY25 and 34.8% in Q3FY26). PAT increased to Rs485mn (10% YoY / +2% QoQ), while PAT margin remained stable at 27% (vs. 28% in Q4FY25 and 28% in Q3FY26).

Concall takeaways: (1) In Pharma, Food & Nutrition segment revenue increased 10% YoY, driven by strong demand from India and Europe. (2) The company was able to pass on the increase in phosphoric acid and sulfuric acid prices to customers. (3) Capacity utilization stood at 65–70%. (4) In Specialty Ingredients segment revenue contribution in FY26 44%. (5) Strong global traction across infant nutrition, medical nutrition and dietary supplements. (6) Capacity utilization stood at 35–40%. (7) In Specialty Ingredients segment received 51 new approvals during FY26. (8) In Battery materials segment Phase-1 commissioning targeted by April'27. (9) Commissioned 5,000–7,000mt battery-grade capacity at the existing facility, with 50% allocated for customer validation and the remaining 50% for commercial sales.

Swarnendu Bhushan
swarnendubhushan@plindia.com | +91-22-66322260

Saurabh Ahire
saurabhahire@plindia.com | +91-22-66322537


Tejas Kadam
tejaskadam@plindia.com | +91-22-66322556

Exhibit 1 : Q4FY26 Result Overview

Y/e March	Q4FY26	Q4FY25	YoY gr. (%)	Q3FY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Net Sales	1,823	1,575	16%	1,723	6%	6,423	5,020	28%
Gross Profit	1,185	978	21%	1,121	6%	4,150	3,372	23%
Margin (%)	65.0%	62.1%		65.1%		64.6%	67.2%	
EBITDA	626	588	6%	600	4%	2,219	1,900	17%
Margin (%)	34.3%	37.3%		34.8%		34.6%	37.8%	
Other Income	64	37		68		286	93	
Depreciation	39	28	37%	39	1%	148	106	40%
EBIT	651	597	9%	629	3%	2,357	1,887	25%
Interest	24	18	35%	12	109%	76	58	30%
PBT before exceptional items	627	579	8%	618	1%	2,281	1,829	25%
Share of Profit of Associate and JV	-	-		-		-	-	
Total Tax	142	137	4%	141	1%	538	441	22%
ETR (%)	23%	24%		23%		24%	24%	
Adj. PAT	485	443	10%	477	2%	1,743	1,387	26%
Exceptional Items	-	-		-		-	-	
PAT	485	443	10%	477	2%	1,743	1,387	26%


Source: Company, PL

Exhibit 2 : Revenue CAGR of 18% over FY25-28E




Source: Company, PL

Exhibit 3 : EBITDA margin to remain at 35% in FY28E




Source: Company, PL

Exhibit 4 : Net debt/Equity to decline going ahead



Source: Company, PL

Exhibit 5 : Return ratios to hover at 15%-17%



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	5,020	6,423	7,276	8,191
YoY gr. (%)	9.3	27.9	13.3	12.6
Cost of Goods Sold	1,648	2,273	2,619	2,949
Gross Profit	3,372	4,150	4,656	5,242
Margin (%)	67.2	64.6	64.0	64.0
Employee Cost	383	519	582	655
Other Expenses	1,089	1,412	1,528	1,720
EBITDA	1,900	2,219	2,546	2,867
YoY gr. (%)	4.6	16.8	14.8	12.6
Margin (%)	37.8	34.6	35.0	35.0
Depreciation and Amortization	106	148	189	285
EBIT	1,794	2,071	2,357	2,582
Margin (%)	35.7	32.2	32.4	31.5
Net Interest	58	76	78	86
Other Income	93	286	291	328
Profit Before Tax	1,829	2,281	2,571	2,824
Margin (%)	36.4	35.5	35.3	34.5
Total Tax	441	538	617	678
Effective Tax Rate (%)	24.1	23.6	24.0	24.0
Profit After Tax	1,387	1,743	1,954	2,146
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,387	1,743	1,954	2,146
YoY gr. (%)	4.2	25.6	12.1	9.8
Margin (%)	27.6	27.1	26.9	26.2
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,387	1,743	1,954	2,146
YoY gr. (%)	4.2	25.6	12.1	9.8
Margin (%)	27.6	27.1	26.9	26.2
Other Comprehensive Income	(16)	(12)	-	-
Total Comprehensive Income	1,371	1,731	1,954	2,146
Equity Shares O/s (mn)	97	113	113	113
EPS (INR)	14.3	15.4	17.3	19.0

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	2,017	2,635	4,135	5,635
Tangibles	2,017	2,635	4,135	5,635
Intangibles	-	-	-	-
Acc: Dep / Amortization	247	395	584	869
Tangibles	247	395	584	869
Intangibles	-	-	-	-
Net Fixed Assets	1,771	2,240	3,551	4,766
Tangibles	1,771	2,240	3,551	4,766
Intangibles	-	-	-	-
Capital Work In Progress	884	1,852	1,852	1,852
Goodwill	-	682	-	-
Non-Current Investments	42	195	221	248
Net Deferred Tax Assets	(40)	(55)	(67)	(81)
Other Non-Current Assets	210	501	567	639
Current Assets				
Investments	1	-	-	-
Inventories	1,287	2,160	1,866	2,100
Trade Receivables	1,854	2,275	2,686	3,024
Cash & Bank Balance	368	267	1,326	1,706
Other Current Assets	629	1,481	1,677	1,888
Total Assets	7,172	11,749	13,848	16,333
Equity				
Equity Share Capital	97	113	113	113
Other Equity	4,834	8,720	10,674	12,820
Total Network	4,931	8,833	10,787	12,933
Non-Current Liabilities				
Long Term Borrowings	396	343	343	343
Provisions	18	-	-	-
Other Non Current Liabilities	17	311	15	17
Current Liabilities				
ST Debt / Current of LT Debt	957	1,140	1,600	1,800
Trade Payables	605	684	775	873
Other Current Liabilities	186	195	221	247
Total Equity & Liabilities	7,172	11,748	13,848	16,333

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	1,829	2,281	2,571	2,824
Add. Depreciation	106	148	189	285
Add. Interest	58	76	78	86
Less Financial Other Income	93	286	291	328
Add. Other	(10)	(134)	-	-
Op. Profit before WC Changes	1,983	2,371	2,838	3,194
Net Changes-WC	(1,090)	(1,121)	(285)	(754)
Direct Tax	(406)	(555)	(617)	(678)
Net Cash from Op. Activities	487	696	1,935	1,763
Capital Expenditures	(639)	(854)	(1,500)	(1,500)
Interest / Dividend Income	1	34	-	-
Others	(150)	(2,489)	-	-
Net Cash from Inv. Activities	(788)	(3,309)	(1,500)	(1,500)
Issue of Share Cap. / Premium	380	70	-	-
Debt Changes	(86)	(103)	-	-
Dividend Paid	-	2,483	-	-
Interest Paid	(54)	(113)	(78)	(86)
Others	287	136	463	203
Net Cash from Fin. Activities	527	2,473	385	117
Net Change in Cash	227	(141)	820	380
Free Cash Flow	(155)	(158)	435	263

Source: Company, PL

Quarterly Financials (INR mn)


Y/e Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Net Revenues	1,249	1,627	1,723	1,823
YoY gr. (%)	55.9	9.3	49.2	15.7
Raw Material Expenses	423	609	602	639
Gross Profit	826	1,017	1,121	1,185
Margin (%)	66.1	62.5	65.1	65.0
EBITDA	439	555	600	626
YoY gr. (%)	54.5	(12.6)	52.6	6.4
Margin (%)	35.1	34.1	34.8	34.3
Depreciation / Depletion	33	38	39	39
EBIT	406	517	561	587
Margin (%)	32.5	31.8	32.6	32.2
Net Interest	17	23	12	24
Other Income	52	102	68	64
Profit before Tax	441	595	618	627
Margin (%)	35.3	36.6	35.8	34.4
Total Tax	128	128	141	142
Effective Tax Rate (%)	29.0	21.4	22.8	22.6
Profit After Tax	313	468	477	485
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	313	468	477	485
YoY gr. (%)	83.0	(4.0)	66.1	9.7
Margin (%)	25.0	28.8	27.7	26.6
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	313	468	477	485
YoY gr. (%)	83.0	(4.0)	66.1	9.7
Margin (%)	25.0	28.8	27.7	26.6
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	313	468	477	485
Avg. Shares O/s (mn)	97	97	113	113
EPS (INR)	3.2	4.8	4.2	4.3

Source: Company, PL

Key Financial Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	14.3	15.4	17.3	19.0
CEPS	15.4	16.7	19.0	21.5
BVPS	50.7	78.2	95.5	114.5
FCF	(1.6)	(1.4)	3.9	2.3
DPS	-	-	-	-
Return Ratio (%)				
RoCE	33.9	25.0	20.5	18.6
ROIC	27.0	19.8	16.7	15.8
RoE	32.7	25.3	19.9	18.1
Balance Sheet				
Net Debt : Equity (x)	0.2	0.1	0.1	-
Net Working Capital (Days)	184	213	189	189
Valuation (x)				
PER	47.1	43.6	38.9	35.4
P/B	13.2	8.6	7.0	5.8
P/CEPS	43.8	40.2	35.4	31.2
EV/EBITDA	34.9	34.8	30.1	26.6
EV/Sales	13.2	12.0	10.5	9.3
Dividend Yield (%)	-	-	-	-
FCFF Yield (%)	-	-	0.5	0.3
PEG Ratio	-	5.3	3.2	3.6

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	24-Apr-26	Reduce	638	682

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Aarti Industries	Accumulate	529	488
2	Bharat Petroleum Corporation	Accumulate	325	294
3	Bharti Airtel	BUY	2226	1884
4	Clean Science and Technology	Hold	846	818
5	Deepak Nitrite	REDUCE	1495	1749
6	Fine Organic Industries	BUY	5353	4607
7	GAIL (India)	Buy	170	145
8	Gujarat Fluorochemicals	HOLD	3316	3330
9	Gujarat Gas	Accumulate	342	313
10	Gujarat State Petronet	Hold	242	236
11	Hindustan Petroleum Corporation	Accumulate	427	390
12	Indian Oil Corporation	Accumulate	145	135
13	Indraprastha Gas	Buy	181	157
14	Jubilant Ingrevia	HOLD	657	635
15	Laxmi Organic Industries	REDUCE	116	125
16	Mahanagar Gas	Accumulate	1302	1174
17	Mangalore Refinery & Petrochemicals	Sell	143	186
18	Navin Fluorine International	Accumulate	7297	6759
19	NOCIL	HOLD	176	182
20	Oil & Natural Gas Corporation	Accumulate	309	287
21	Oil India	Accumulate	550	507
22	Petronet LNG	Accumulate	310	283
23	Reliance Industries	BUY	1635	1328
24	SRF	REDUCE	2579	2720
25	Sudeep Pharma	Reduce	638	682
26	Vinati Organics	Accumulate	1475	1288

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution of third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.